Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07498517 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07498517: Clinical Trial Phase 2 study, sponsored by OHSU Knight Cancer Institute.
NCT07498517 is a Phase 2 study that has not yet begun recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07498517, a Phase 2 study, has not yet begun recruiting, sponsored by OHSU Knight Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Gruticibart, a type of drug called a monoclonal antibody, may prevent blood clots caused by a catheter.
Primary Outcome
Defined by the total incidence of symptomatic and asymptomatic thrombosis.
Interventions
- DRUG Placebo
- PROCEDURE Ultrasound
- DRUG Gruticibart
- PROCEDURE Biopspecimen collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-02-28 |
| Est. Completion | 2029-10-02 |
| Phase | Phase 2 |
What is known before NCT07498517 opens enrollment
NCT07498517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07498517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07498517 about?
NCT07498517 is a clinical study titled "Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT". This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They al...
What is the current status of trial NCT07498517?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-02-28. Estimated completion is 2029-10-02.
What interventions are being tested in trial NCT07498517?
The interventions under investigation include: Placebo (DRUG), Ultrasound (PROCEDURE), Gruticibart (DRUG), Biopspecimen collection (PROCEDURE).
Who is sponsoring clinical trial NCT07498517?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07498517's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI